Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med - Takeda Pharmaceutical Co (NYSE:

Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

Zasocitinib outperformed Sotyktu 2.5x on complete psoriasis clearance, validating Takeda's $4B drug-discovery acquisition. The result signals market shift toward oral therapies, expected to triple in a decade, reshaping competitive strategy and budget allocation in biopharma.